ABOS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
32.6M
+53.9%
21.1M
-16.1%
25.2M
-5.0%
26.5M
-36.5%
41.8M
R&D
27.8M
+68.7%
16.5M
-19.7%
20.5M
-6.6%
22.0M
-40.8%
37.1M
SG&A
4.7M
+1.8%
4.7M
-0.2%
4.7M
+2.8%
4.5M
-1.7%
4.6M
Operating Income
-32556000
-53.9%
-21149000
+16.1%
-25199000
+5.0%
-26513000
+36.5%
-41750000
EBITDA
-32545000
-54.0%
-21137000
+16.1%
-25187000
+4.9%
-26498000
+36.5%
-41734000
Net Income
-32718000
-57.8%
-20737000
+17.5%
-25138000
+5.0%
-26451000
+35.4%
-40950000
EPS (Basic)
$-0.45
-36.4%
$-0.33
+19.5%
$-0.41
+6.8%
$-0.44
+35.3%
$-0.68
EPS (Diluted)
$-0.45
-36.4%
$-0.33
+19.5%
$-0.41
+6.8%
$-0.44
+35.3%
$-0.68
Shares (Diluted)
72.3M
+14.3%
63.2M
+4.4%
60.6M
+0.0%
60.6M
+0.0%
60.6M
Acumen Pharmaceuticals (ABOS) โ€” Financials